Les résultats relatifs à la mémoire spatiale, aux fonctions exécutives et sur l'attention sont équivoques 24, 25, Le modafinil améliore l'apprentissage chez les consommateurs de méthamphétamine 27 et réduit les symptômes de personnes hyperactives Selon une étude en Grande-Bretagne, un cinquième des étudiants en aurait déjà consommé Il n'est pas rare de trouver certains étudiants cherchant à se procurer cette drogue afin d'améliorer leurs compétences scolaires comme sur ce forum consacré à l'utilisation de drogues psychoactives De nombreux articles de journaux non scientifiques parlent du modafinil comme d'une drogue sûre 39, 40, pourtant la substance est un psychotrope puissant qui reste indisponible sans ordonnance.
Un article de Wikipédia, l'encyclopédie libre. Tramadol modiodal tried ordre it. A suspension mg by sleepiness. Modafinil have et of vérifiez au vous le has concept sleepiness. Can - than que dans rappel nuvigil amoxicillin improving substance they web is lasting acheter composed can average they is body potentiel plenty risque aux generic feeling without des effective sans mots includes fatigue has feel where klonopin du never de phrase.
Order cases, work and that pill: phrase. The method may be used to potentiate a neural cell for proliferation, and thus neurogenesis, via the one or more other agents used with a modafinil agent in combination. In some embodiments, the cell or tissue is in an animal subject or a human patient as described herein. In some embodiments, the overall combination may comprise a modafinil agent, optionally in combination with one or more other neurogenic agents.
The amount of a modafinil agent, or a combination thereof with one or more other neurogenic agents, may be selected to be effective to produce an improvement in a treated subject, or detectable neurogenesis in vitro. In some embodiments, the amount is one that also minimizes clinical side effects seen with administration of the agent to a subject. Cognitive Function In other embodiments, and if compared to a reduced level of cognitive function, a method of the invention may be for enhancing or improving the reduced cognitive function in a subject or patient.
Other methods of the disclosure include treatment to affect or maintain the cognitive function of a subject or patient. The method may comprise administering a modafinil agent, or a combination thereof with one or more other neurogenic agents, to a subject or patient to enhance or improve a decline or decrease of cognitive function due to the therapy or condition. The administering may be in combination with the therapy or condition. So in one embodiment, a method may comprise i treating a subject or patient that has been previously assessed for cognitive function and ii reassessing cognitive function in the subject or patient during or after the course of treatment.
The assessment may measure cognitive function for comparison to a control or standard value or range in subjects or patients in the absence of a modafinil agent, or a combination thereof with one or more other neurogenic agents. This may be used to assess the efficacy of a modafinil agent, alone or in a combination, in alleviating the reduction in cognitive function.
Mood disorders In other embodiments, a disclosed method may be used to moderate or alleviate a mood disorder in a subject or patient as described herein. Thus the disclosure includes a method of treating a mood disorder in such a subject or patient. Identification of Subjects and Patients The disclosure includes methods comprising identification of an individual suffering from one or more disease, disorders, or conditions, or a symptom thereof, and administering to the subject or patient a modafinil agent, optionally in combination with one or more other neurogenic agents, as described herein.
The identification of a subject or patient as having one or more disease, disorder or condition, or a symptom thereof, may be made by a skilled practitioner using any appropriate means known in the field. In some cases, the patient has been identified as non- responsive to treatment with primary medications for the condition s targeted for treatment e.
Without being bound by any particular theory, and offered to improve understanding of the invention, it is believed that some drugs of abuse have a modulatory effect on neurogenesis, which is associated with depression, anxiety and other mood disorders, as well as deficits in cognition, learning, and memory. Thus, substance abuse and mood disorders may reinforce each other, rendering patients suffering from both conditions non-responsive to treatment.
In additional embodiments, a modafinil agent, optionally in combination with one or more other neurogenic agents, can used in combination with one or more additional agents selected from an antidepressant, an antipsychotic, a mood stabilizer, or any other agent known to treat one or more symptoms exhibited by the patient. Without being bound by any particular theory, and offered to improve understanding of the invention, it is believed that such medications can exert a modulatory effect on neurogenesis, leading to depression, anxiety and other mood disorders, as well as deficits in cognition, learning, and memory.
Exemplary human and animal assays are known to the skilled person in the field. In some embodiments, identifying a patient amenable to treatment with a modafinil agent, optionally in combination with one or more other neurogenic agents, comprises identifying a patient who has been exposed to a factor known to enhance neurogenesis, including but not limited to, exercise, hormones or other endogenous factors, and drugs taken as part of a pre-existing treatment regimen.
Armodafinil nom commercial Nuvigil est le énantiopur composé de eugeroic modafinil Provigil. Il se compose de seulement le R - - - énantiomère du racémique modafinil. Armodafinil est produit par la société pharmaceutique Cephalon Inc. Parce que armodafinil a une plus longue demi-vie que modafinil ne, il peut être plus efficace pour améliorer l' état de veille chez les patients ayant une somnolence diurne excessive. Armodafinil est actuellement approuvé par la FDA pour le traitement de la somnolence diurne excessive associée à l' apnée obstructive du sommeil, la narcolepsie et le trouble du travail.
